vs
Celldex Therapeutics, Inc.（CLDX）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是Celldex Therapeutics, Inc.的1872.4倍（$224.7M vs $120.0K）。NEOGEN CORP净利率更高（-7.1% vs -67764.2%，领先67757.1%）。NEOGEN CORP同比增速更快（-2.8% vs -89.8%）。NEOGEN CORP自由现金流更多（$7.8M vs $-65.2M）。过去两年NEOGEN CORP的营收复合增速更高（-0.9% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
CLDX vs NEOG — 直观对比
营收规模更大
NEOG
是对方的1872.4倍
$120.0K
营收增速更快
NEOG
高出86.9%
-89.8%
净利率更高
NEOG
高出67757.1%
-67764.2%
自由现金流更多
NEOG
多$73.0M
$-65.2M
两年增速更快
NEOG
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $224.7M |
| 净利润 | $-81.3M | $-15.9M |
| 毛利率 | — | 47.5% |
| 营业利润率 | -72628.3% | -2.4% |
| 净利率 | -67764.2% | -7.1% |
| 营收同比 | -89.8% | -2.8% |
| 净利润同比 | -72.7% | 96.5% |
| 每股收益（稀释后） | $-1.23 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXNEOG
| Q4 25 | $120.0K | $224.7M | ||
| Q3 25 | $0 | $209.2M | ||
| Q2 25 | $730.0K | $225.4M | ||
| Q1 25 | $695.0K | $221.0M | ||
| Q4 24 | $1.2M | $231.3M | ||
| Q3 24 | $3.2M | $217.0M | ||
| Q2 24 | $2.5M | $236.8M | ||
| Q1 24 | $156.0K | $228.8M |
净利润CLDXNEOG
| Q4 25 | $-81.3M | $-15.9M | ||
| Q3 25 | $-67.0M | $36.3M | ||
| Q2 25 | $-56.6M | $-612.3M | ||
| Q1 25 | $-53.8M | $-10.9M | ||
| Q4 24 | $-47.1M | $-456.3M | ||
| Q3 24 | $-42.1M | $-12.6M | ||
| Q2 24 | $-35.8M | $-5.4M | ||
| Q1 24 | $-32.8M | $-2.0M |
毛利率CLDXNEOG
| Q4 25 | — | 47.5% | ||
| Q3 25 | — | 45.4% | ||
| Q2 25 | — | 41.2% | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | 49.0% | ||
| Q3 24 | — | 48.4% | ||
| Q2 24 | — | 47.9% | ||
| Q1 24 | — | 51.1% |
营业利润率CLDXNEOG
| Q4 25 | -72628.3% | -2.4% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | -8747.5% | -271.1% | ||
| Q1 25 | -9027.2% | 2.4% | ||
| Q4 24 | -4768.3% | -197.8% | ||
| Q3 24 | -1633.5% | 1.0% | ||
| Q2 24 | -1854.2% | 5.5% | ||
| Q1 24 | -26030.8% | 5.3% |
净利率CLDXNEOG
| Q4 25 | -67764.2% | -7.1% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | -7753.4% | -271.6% | ||
| Q1 25 | -7740.4% | -4.9% | ||
| Q4 24 | -4007.8% | -197.3% | ||
| Q3 24 | -1320.0% | -5.8% | ||
| Q2 24 | -1434.8% | -2.3% | ||
| Q1 24 | -21030.8% | -0.9% |
每股收益（稀释后）CLDXNEOG
| Q4 25 | $-1.23 | $-0.07 | ||
| Q3 25 | $-1.01 | $0.17 | ||
| Q2 25 | $-0.85 | $-2.82 | ||
| Q1 25 | $-0.81 | $-0.05 | ||
| Q4 24 | $-0.71 | $-2.10 | ||
| Q3 24 | $-0.64 | $-0.06 | ||
| Q2 24 | $-0.54 | $-0.02 | ||
| Q1 24 | $-0.56 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $145.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $527.2M | $2.1B |
| 总资产 | $583.0M | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLDXNEOG
| Q4 25 | $518.6M | $145.3M | ||
| Q3 25 | $583.2M | $138.9M | ||
| Q2 25 | $630.3M | $129.0M | ||
| Q1 25 | $673.3M | $127.7M | ||
| Q4 24 | $725.3M | $140.2M | ||
| Q3 24 | $756.0M | $120.5M | ||
| Q2 24 | $802.3M | $170.9M | ||
| Q1 24 | $823.8M | $168.4M |
股东权益CLDXNEOG
| Q4 25 | $527.2M | $2.1B | ||
| Q3 25 | $598.4M | $2.1B | ||
| Q2 25 | $655.4M | $2.1B | ||
| Q1 25 | $703.0M | $2.7B | ||
| Q4 24 | $747.0M | $2.7B | ||
| Q3 24 | $785.9M | $3.1B | ||
| Q2 24 | $813.7M | $3.1B | ||
| Q1 24 | $838.6M | $3.1B |
总资产CLDXNEOG
| Q4 25 | $583.0M | $3.4B | ||
| Q3 25 | $648.4M | $3.4B | ||
| Q2 25 | $692.4M | $3.4B | ||
| Q1 25 | $739.5M | $4.0B | ||
| Q4 24 | $792.3M | $4.1B | ||
| Q3 24 | $823.2M | $4.5B | ||
| Q2 24 | $845.6M | $4.5B | ||
| Q1 24 | $868.8M | $4.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $7.8M |
| 自由现金流率自由现金流/营收 | -54350.8% | 3.5% |
| 资本支出强度资本支出/营收 | 1067.5% | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $-18.5M |
8季度趋势，按日历期对齐
经营现金流CLDXNEOG
| Q4 25 | $-63.9M | $19.4M | ||
| Q3 25 | $-48.6M | $10.9M | ||
| Q2 25 | $-44.0M | $16.4M | ||
| Q1 25 | $-54.4M | $19.5M | ||
| Q4 24 | $-32.5M | $40.3M | ||
| Q3 24 | $-55.3M | $-17.9M | ||
| Q2 24 | $-29.3M | $26.7M | ||
| Q1 24 | $-40.6M | $-30.2M |
自由现金流CLDXNEOG
| Q4 25 | $-65.2M | $7.8M | ||
| Q3 25 | $-49.1M | $-13.1M | ||
| Q2 25 | $-44.7M | $349.0K | ||
| Q1 25 | $-54.6M | $-13.4M | ||
| Q4 24 | $-33.2M | $23.1M | ||
| Q3 24 | $-55.9M | $-56.3M | ||
| Q2 24 | $-29.6M | $2.5M | ||
| Q1 24 | $-41.0M | $-62.3M |
自由现金流率CLDXNEOG
| Q4 25 | -54350.8% | 3.5% | ||
| Q3 25 | — | -6.3% | ||
| Q2 25 | -6127.8% | 0.2% | ||
| Q1 25 | -7861.4% | -6.1% | ||
| Q4 24 | -2828.3% | 10.0% | ||
| Q3 24 | -1751.2% | -26.0% | ||
| Q2 24 | -1185.0% | 1.1% | ||
| Q1 24 | -26270.5% | -27.2% |
资本支出强度CLDXNEOG
| Q4 25 | 1067.5% | 5.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | 99.7% | 7.1% | ||
| Q1 25 | 38.1% | 14.9% | ||
| Q4 24 | 64.3% | 7.4% | ||
| Q3 24 | 17.1% | 17.7% | ||
| Q2 24 | 11.0% | 10.2% | ||
| Q1 24 | 220.5% | 14.0% |
现金转化率CLDXNEOG
| Q4 25 | — | — | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDX
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
